Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitamin A Deficiency | 1 | 2025 | 13 | 0.960 |
Why?
|
| Corneal Diseases | 1 | 2025 | 25 | 0.940 |
Why?
|
| Strabismus | 6 | 2021 | 20 | 0.910 |
Why?
|
| Retinopathy of Prematurity | 5 | 2014 | 40 | 0.800 |
Why?
|
| Glycogen Storage Disease Type II | 3 | 2014 | 3 | 0.770 |
Why?
|
| Blepharoptosis | 3 | 2014 | 7 | 0.770 |
Why?
|
| Glaucoma | 6 | 2020 | 53 | 0.730 |
Why?
|
| Intraocular Pressure | 7 | 2020 | 62 | 0.600 |
Why?
|
| Myopia | 4 | 2014 | 19 | 0.590 |
Why?
|
| Enzyme Replacement Therapy | 3 | 2014 | 4 | 0.530 |
Why?
|
| Oculomotor Muscles | 3 | 2014 | 18 | 0.510 |
Why?
|
| Shaken Baby Syndrome | 1 | 2016 | 5 | 0.490 |
Why?
|
| Craniocerebral Trauma | 1 | 2016 | 27 | 0.480 |
Why?
|
| Child, Preschool | 8 | 2025 | 1167 | 0.480 |
Why?
|
| Child Abuse | 1 | 2016 | 92 | 0.450 |
Why?
|
| alpha-Glucosidases | 2 | 2014 | 4 | 0.440 |
Why?
|
| Ophthalmology | 3 | 2021 | 37 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 164 | 0.430 |
Why?
|
| Antihypertensive Agents | 3 | 2020 | 56 | 0.410 |
Why?
|
| Retinal Vessels | 2 | 2009 | 75 | 0.360 |
Why?
|
| Vision Screening | 1 | 2010 | 5 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2012 | 550 | 0.340 |
Why?
|
| Down Syndrome | 1 | 2010 | 19 | 0.340 |
Why?
|
| Vision Disorders | 1 | 2010 | 38 | 0.330 |
Why?
|
| Humans | 27 | 2025 | 28581 | 0.320 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2009 | 6 | 0.310 |
Why?
|
| Cloprostenol | 1 | 2009 | 3 | 0.300 |
Why?
|
| Male | 14 | 2025 | 13771 | 0.280 |
Why?
|
| Child | 9 | 2020 | 2271 | 0.280 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 233 | 0.280 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2007 | 9 | 0.270 |
Why?
|
| Adolescent | 8 | 2020 | 3165 | 0.270 |
Why?
|
| Internship and Residency | 2 | 2021 | 250 | 0.260 |
Why?
|
| Visual Acuity | 3 | 2025 | 119 | 0.260 |
Why?
|
| Infant, Newborn | 6 | 2016 | 899 | 0.260 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 461 | 0.260 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2006 | 23 | 0.250 |
Why?
|
| Cost of Illness | 1 | 2006 | 54 | 0.240 |
Why?
|
| Vitamin A | 1 | 2025 | 32 | 0.240 |
Why?
|
| Collagen Type II | 2 | 2017 | 12 | 0.230 |
Why?
|
| Retinal Detachment | 2 | 2017 | 11 | 0.230 |
Why?
|
| Infant | 6 | 2020 | 1019 | 0.230 |
Why?
|
| Connective Tissue Diseases | 2 | 2017 | 13 | 0.230 |
Why?
|
| Arthritis | 2 | 2017 | 29 | 0.230 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2017 | 24 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 244 | 0.220 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 633 | 0.200 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 31 | 0.190 |
Why?
|
| Teaching | 2 | 2021 | 83 | 0.190 |
Why?
|
| Filtering Surgery | 3 | 2020 | 9 | 0.180 |
Why?
|
| Mutation | 3 | 2016 | 864 | 0.170 |
Why?
|
| Cytoskeletal Proteins | 2 | 2012 | 42 | 0.170 |
Why?
|
| Curriculum | 2 | 2021 | 296 | 0.170 |
Why?
|
| Insulin | 2 | 1999 | 323 | 0.170 |
Why?
|
| Female | 12 | 2020 | 15471 | 0.170 |
Why?
|
| Glycoproteins | 2 | 2012 | 123 | 0.160 |
Why?
|
| Glycogen | 2 | 2010 | 23 | 0.160 |
Why?
|
| Receptor, TIE-2 | 2 | 2017 | 9 | 0.160 |
Why?
|
| Codon, Nonsense | 2 | 2017 | 11 | 0.160 |
Why?
|
| Cataract Extraction | 1 | 2020 | 29 | 0.160 |
Why?
|
| Eye Proteins | 2 | 2012 | 207 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 117 | 0.150 |
Why?
|
| Astrocytes | 1 | 1999 | 79 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2020 | 893 | 0.140 |
Why?
|
| Angiopoietin-1 | 1 | 2017 | 8 | 0.140 |
Why?
|
| Glaucoma Drainage Implants | 2 | 2007 | 10 | 0.140 |
Why?
|
| Lymphatic Vessels | 1 | 2017 | 22 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2010 | 2402 | 0.130 |
Why?
|
| Penetrance | 1 | 2017 | 5 | 0.130 |
Why?
|
| United States | 4 | 2016 | 2201 | 0.130 |
Why?
|
| Jurisprudence | 1 | 2016 | 5 | 0.120 |
Why?
|
| Liability, Legal | 1 | 2016 | 5 | 0.120 |
Why?
|
| Health Surveys | 1 | 2016 | 84 | 0.120 |
Why?
|
| Exome | 4 | 2017 | 32 | 0.110 |
Why?
|
| Incidence | 3 | 2020 | 568 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2014 | 2612 | 0.110 |
Why?
|
| Pedigree | 4 | 2017 | 155 | 0.110 |
Why?
|
| Pediatrics | 1 | 2016 | 92 | 0.110 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2014 | 8 | 0.110 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2014 | 22 | 0.110 |
Why?
|
| Astigmatism | 1 | 2014 | 11 | 0.110 |
Why?
|
| Infant, Premature, Diseases | 1 | 2014 | 37 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2017 | 1454 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2013 | 2 | 0.100 |
Why?
|
| Infant, Premature | 1 | 2014 | 144 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2014 | 245 | 0.100 |
Why?
|
| Hydrophthalmos | 1 | 2012 | 2 | 0.100 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 4 | 0.100 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2012 | 3 | 0.100 |
Why?
|
| Mitochondrial Proteins | 1 | 2013 | 80 | 0.100 |
Why?
|
| DNA | 1 | 2014 | 375 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 2 | 2009 | 58 | 0.090 |
Why?
|
| Penicillamine | 1 | 2011 | 9 | 0.090 |
Why?
|
| Chelating Agents | 1 | 2011 | 22 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2013 | 252 | 0.090 |
Why?
|
| Retinal Degeneration | 1 | 2013 | 151 | 0.090 |
Why?
|
| Risk Factors | 3 | 2020 | 2111 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 782 | 0.090 |
Why?
|
| Refractive Errors | 1 | 2010 | 6 | 0.090 |
Why?
|
| Gestational Age | 2 | 2014 | 146 | 0.090 |
Why?
|
| Amblyopia | 1 | 2010 | 6 | 0.090 |
Why?
|
| Muscle Weakness | 1 | 2010 | 16 | 0.080 |
Why?
|
| DNA Mutational Analysis | 3 | 2017 | 93 | 0.080 |
Why?
|
| Oxygen | 1 | 2011 | 234 | 0.080 |
Why?
|
| Prostaglandins F, Synthetic | 1 | 2009 | 3 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 671 | 0.080 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2009 | 23 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2010 | 122 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2009 | 12 | 0.080 |
Why?
|
| Venules | 1 | 2009 | 3 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 480 | 0.080 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2009 | 5 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 524 | 0.080 |
Why?
|
| Travoprost | 1 | 2009 | 1 | 0.080 |
Why?
|
| Dilatation, Pathologic | 1 | 2009 | 11 | 0.080 |
Why?
|
| Arterioles | 1 | 2009 | 61 | 0.080 |
Why?
|
| Prevalence | 1 | 2010 | 510 | 0.080 |
Why?
|
| Photography | 1 | 2009 | 19 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 415 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 611 | 0.070 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2009 | 58 | 0.070 |
Why?
|
| Haplotypes | 1 | 2009 | 284 | 0.070 |
Why?
|
| Disease Progression | 1 | 2010 | 475 | 0.070 |
Why?
|
| Eye Movements | 1 | 2007 | 12 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 1026 | 0.070 |
Why?
|
| Aged | 3 | 2017 | 5525 | 0.070 |
Why?
|
| Trabecular Meshwork | 2 | 2017 | 16 | 0.070 |
Why?
|
| Mice | 5 | 2017 | 4732 | 0.060 |
Why?
|
| Animals | 6 | 2017 | 10580 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 114 | 0.060 |
Why?
|
| Birth Weight | 1 | 2006 | 63 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 638 | 0.060 |
Why?
|
| Adult | 3 | 2017 | 7922 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 270 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2017 | 861 | 0.050 |
Why?
|
| Middle Aged | 2 | 2017 | 7310 | 0.050 |
Why?
|
| Phenotype | 2 | 2016 | 682 | 0.050 |
Why?
|
| Base Sequence | 2 | 2013 | 588 | 0.050 |
Why?
|
| Linkage Disequilibrium | 2 | 2014 | 108 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 1056 | 0.040 |
Why?
|
| Family | 2 | 2013 | 98 | 0.040 |
Why?
|
| Aphakia, Postcataract | 1 | 2020 | 1 | 0.040 |
Why?
|
| Ocular Hypertension | 1 | 2020 | 11 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 1999 | 419 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 1999 | 1009 | 0.040 |
Why?
|
| Cataract | 1 | 2020 | 26 | 0.040 |
Why?
|
| Neurofilament Proteins | 1 | 1998 | 5 | 0.040 |
Why?
|
| Fetus | 1 | 1999 | 79 | 0.040 |
Why?
|
| Rats | 2 | 1999 | 1587 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2016 | 581 | 0.040 |
Why?
|
| Aphakia | 2 | 2007 | 3 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2017 | 20 | 0.030 |
Why?
|
| Aqueous Humor | 2 | 2007 | 24 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 393 | 0.030 |
Why?
|
| Prosthesis Design | 2 | 2007 | 88 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 458 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 994 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2017 | 128 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2017 | 95 | 0.030 |
Why?
|
| Angiopoietins | 1 | 2016 | 1 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2017 | 68 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2016 | 35 | 0.030 |
Why?
|
| Neurons | 1 | 1998 | 291 | 0.030 |
Why?
|
| Family Health | 1 | 2016 | 71 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2016 | 70 | 0.030 |
Why?
|
| Ligands | 1 | 2016 | 178 | 0.030 |
Why?
|
| Iris | 1 | 2014 | 8 | 0.030 |
Why?
|
| Ciliary Body | 1 | 2014 | 7 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 509 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2014 | 41 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 166 | 0.030 |
Why?
|
| Brain | 1 | 1999 | 753 | 0.030 |
Why?
|
| Versicans | 1 | 2013 | 2 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 2013 | 35 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2013 | 78 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2013 | 50 | 0.020 |
Why?
|
| Point Mutation | 1 | 2013 | 60 | 0.020 |
Why?
|
| Copper | 1 | 2013 | 49 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2012 | 7 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2013 | 119 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 465 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 376 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2011 | 35 | 0.020 |
Why?
|
| Intravitreal Injections | 1 | 2011 | 34 | 0.020 |
Why?
|
| Retinal Neovascularization | 1 | 2011 | 21 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 72 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2011 | 181 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 667 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 732 | 0.020 |
Why?
|
| Tonometry, Ocular | 1 | 2009 | 9 | 0.020 |
Why?
|
| Reference Standards | 1 | 2009 | 57 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2009 | 59 | 0.020 |
Why?
|
| ROC Curve | 1 | 2009 | 144 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 185 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 107 | 0.020 |
Why?
|
| Depth Perception | 1 | 2007 | 3 | 0.020 |
Why?
|
| Retina | 1 | 2011 | 437 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 1494 | 0.020 |
Why?
|
| Time Factors | 1 | 2007 | 1600 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2007 | 631 | 0.010 |
Why?
|
| Sympathomimetics | 1 | 1998 | 1 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 1998 | 12 | 0.010 |
Why?
|
| Isoproterenol | 1 | 1998 | 23 | 0.010 |
Why?
|
| Flavonoids | 1 | 1998 | 32 | 0.010 |
Why?
|
| Cricetinae | 1 | 1998 | 131 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 1998 | 45 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 251 | 0.010 |
Why?
|